Side-by-side comparison of AI visibility scores, market position, and capabilities
FY2024 Revenue: $372.8B (+4.2% YoY) | Net income: $4.6B (down from $8.4B) | Operating income: $8.5B (-38% YoY) | Q4 2024: $97.7B | Healthcare benefits segment challenged
CVS Health Corporation is one of the largest healthcare companies in the United States, formed through a series of major acquisitions that transformed CVS Pharmacy — a retail drugstore chain founded in Lowell, Massachusetts in 1963 — into a vertically integrated healthcare enterprise. Key acquisitions include Caremark Rx (pharmacy benefit management, 2007), Aetna (health insurance, $69 billion, 2018), and Oak Street Health (primary care clinics, 2023). CVS Health's model positions the company as a healthcare touchpoint spanning insurance enrollment, prescription management, and clinical care delivery.\n\nCVS Health's segments include Health Care Benefits (Aetna insurance for employer groups, Medicare, and Medicaid), Health Services (Caremark PBM, specialty pharmacy, infusion), and Pharmacy & Consumer Wellness (retail operations). CVS operates 9,000+ pharmacy locations and is expanding MinuteClinic and HealthHUB formats that co-locate clinical services with pharmacy for primary and chronic care management. The company also operates pharmacy-only conversion locations removing front-end retail to concentrate on health services.\n\nCVS Health reported FY2024 revenue of $372.8 billion (+4.2% YoY) with net income of approximately $4.6 billion. Near-term pressure on Aetna's Medicare Advantage business — elevated medical cost ratios from post-pandemic care utilization — has driven benefit redesigns and market exits. Despite these headwinds, CVS Health's vertically integrated model combining PBM leverage, insurance membership, and retail pharmacy access represents a structurally unique healthcare asset at scale.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.